12
NEWS
Type 1 & tech
Diabetes UK's third annual Type 1 &
Tech conference returns on Saturday
15 October 2022 from 10am-2.30pm.
The online conference, for people
living with Type 1 diabetes, their
parents and carers, is promised to
be packed with interactive content
to increase confidence about the
exciting but complex world of
diabetes tech. Specifically, the day
will include: a toolkit session on how
to have a quality conversation with
an HCP about diabetes technology; a
review of what the current guidelines
are; and "a whistle-stop journey
starting in the past, going around
the world in 60 seconds and ending
in the future, hearing stories from
around the globe about tech and how
it has improved the lives of so many
people with T1D." To read more - and
to register - CLICK HERE.
CE Mark for Omnipod 5
After months of regulatory delays, Insulet has secured a CE Mark for its Omnipod 5, its automated Insulin Delivery
System for individuals aged two years and older with Type 1 diabetes.
The tubeless hybrid closed loop system integrates with the Dexcom G6 continuous glucose monitoring system
to automatically adjust insulin delivery. The receipt of the CE Mark under the European Union's Medical Device
Regulations comes weeks after the Food and Drug Administration approved it for use in children aged two years and
upwards in the USA. Insulet expects to use the CE Mark to make the device available in "select countries" from the
middle of next year onward.
"There is tremendous enthusiasm for Omnipod 5 from the global diabetes community, and we are thrilled to have
achieved this latest milestone," said Jim Hollingshead, President and CEO of Insulet. "With Omnipod 5, customers can
enjoy the lifestyle benefits of a tubeless, wearable innovation and achieve positive clinical outcomes while managing
their diabetes."
Omnipod 5 is the first CE marked tubeless hybrid closed loop system (also known as automated insulin delivery)
that integrates with the Dexcom G6 Continuous Glucose Monitoring (CGM) System to automatically adjust insulin and
help protect against high and low glucose levels . The system consists of the tubeless Pod enhanced with SmartAdjust
technology, the Omnipod 5 Controller with its integrated SmartBolus Calculator, and the Dexcom G6 CGM.
Every five minutes, SmartAdjust technology receives a CGM value and trend, and predicts where glucose will be 60
minutes into the future. The system then increases, decreases, or pauses insulin delivery based on the user's desired
and customized glucose target.
"This is a significant step forward for people in Europe living with diabetes," said Kevin Sayer, Chairman, President
and CEO of Dexcom. "We're proud to partner with Insulet, combining our industry-leading Dexcom G6 CGM
technology with their tubeless, wearable insulin delivery system, to improve clinical outcomes and reduce the burden
of glucose management for people with diabetes."
To read more, CLICK HERE.
Blue Balloon Campaign
Medtronic is adding extra power to its fun, amusing and clever campaign to
raise awareness of what it's like to live with diabetes. It says it's like keeping
a balloon in the air all the time, even while doing other tasks, a constant
balancing act. Submitting videos of people doing this will raise money to the
charity Spare A Rose. To find out more, click HERE.